<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/kura-oncology-inc-logo-1200x675.jpg/query-dj0yMDI0MDUxNTA5MzgwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/kura-oncology-inc-logo-1200x675.jpg/query-dj0yMDI0MDUxNTA5MzgwNQ"/>Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) SVP Thomas James Doyle sold 7,142 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $60,421.32. Following the transaction, the senior vice president owned 145,167 shares of the company's stock, valued at $1,228,112.82. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.</p><ul><li>Is Kintara Therapeutics A Hidden Gem?</li></ul><p>Thomas James Doyle also recently made the following trade(s): </p><ul><li>On Friday, November 14th, Thomas James Doyle sold 4,539 shares of Kura Oncology stock. The shares were sold at an average price of $11.18, for a total transaction of $50,746.02. </li></ul><h2>Kura Oncology Price Performance</h2><p>Shares of KURA opened at $8.47 on Wednesday. The company's 50-day moving average is $10.33 and its 200-day moving average is $9.05. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. The firm has a market capitalization of $737.06 million, a PE ratio of -3.42 and a beta of 0.25. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $12.49. </p><hr/><hr/><p>Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.28). The company had revenue of $20.75 million during the quarter, compared to analyst estimates of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%.  Equities analysts forecast that  Kura Oncology, Inc. will post -2.44 EPS for the current year. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of research analysts have commented on the company. Leerink Partners  set a $20.00 price objective on Kura Oncology and gave the company an &#34;outperform&#34; rating in a report on Tuesday, January 13th. UBS Group upped their price target on shares of Kura Oncology from $14.00 to $16.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, November 14th. Zacks Research cut shares of Kura Oncology from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Tuesday, January 20th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Kura Oncology in a report on Thursday, January 22nd. Finally, Wedbush  reaffirmed an &#34;outperform&#34; rating and set a $38.00 target price (up from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. Nine research analysts have rated the stock with a Buy rating, two have issued  a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $28.00.</p><p><b>View Our Latest Analysis on Kura Oncology</b></p><h2>Hedge Funds Weigh In On Kura Oncology</h2><p>Several hedge funds have recently bought and sold shares of the company. Assenagon Asset Management S.A. boosted its stake in  Kura Oncology by 37.6% in the third quarter. Assenagon Asset Management S.A. now owns 1,265,030 shares of the company's stock valued at $11,196,000 after buying an additional 345,951 shares in the last quarter.  Sector Gamma AS bought a new position in shares of  Kura Oncology in the third quarter worth about $3,880,000.  Wealth Enhancement Advisory Services LLC boosted its stake in shares of  Kura Oncology by 169.3% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 56,912 shares of the company's stock valued at $334,000 after purchasing an additional 35,779 shares in the last quarter.  Los Angeles Capital Management LLC bought a new stake in shares of  Kura Oncology during the 2nd quarter valued at approximately $450,000.  Finally, Geode Capital Management LLC grew its holdings in shares of  Kura Oncology by 11.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company's stock valued at $11,623,000 after purchasing an additional 211,470 shares during the last quarter. </p><h2>More Kura Oncology News</h2><p>Here are the key news stories impacting Kura Oncology this week:</p><ul>   <li><span>Negative Sentiment: </span>Teresa Brophy Bair (insider) sold 11,208 shares at an average price of $8.46 for proceeds of $94,819.68; her post-sale holdings are 226,931 shares (down ~4.71%). Read More.</li>    <li><span>Negative Sentiment: </span>Francis Burrows (insider) sold 1,311 shares at $8.46 for proceeds of $11,091.06; post-sale holdings 32,424 shares (down ~3.89%). Read More.</li>    <li><span>Negative Sentiment: </span>Thomas James Doyle (SVP) sold 7,142 shares at $8.46 for proceeds of $60,421.32; post-sale holdings 145,167 shares (down ~4.69%). Read More.</li>    <li><span>Negative Sentiment: </span>Mollie Leoni (insider) sold 8,180 shares at $8.46 for proceeds of $69,202.80; post-sale holdings 267,274 shares (down ~2.97%). Read More.</li>    <li><span>Negative Sentiment: </span>Kathleen Ford (COO) sold 1,813 shares at $8.46 for proceeds of $15,337.98; post-sale holdings 153,560 shares (down ~1.17%). Read More.</li> </ul><h2>About Kura Oncology</h2><p> (Get Free Report)</p><p>Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.  </p><p>The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Kura Oncology</li><li>America's Next Power Move Starts Underground</li><li>Your Signature Is Missing – Act Before It’s Too Late</li><li>URGENT: Trump Just Triggered AI’s Biggest Disruption Yet</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The biggest scam in the history of gold markets is unwinding</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1VSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1VSQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Kura Oncology?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Kura Oncology and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://edgeonthestreet.com/wp-content/uploads/2025/11/battery-nuclear-jet.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="900" height="600" original-src="https://imageproxy.pbkrs.com/https://edgeonthestreet.com/wp-content/uploads/2025/11/battery-nuclear-jet.jpg"/></p><div><p>America's Next Power Move Starts Underground</p><p>Washington's New Metals Push Looks to Spark a U.S. Comeback  America's next industrial revolution may not ha...</p><p><span>i2i Marketing Group, LLC</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzM3Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzM3Mw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://3328.efuserassets.com/3328/offers/34/c/1400/assets/Letter-DJT.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1536" height="1024" original-src="https://imageproxy.pbkrs.com/https://3328.efuserassets.com/3328/offers/34/c/1400/assets/Letter-DJT.png"/></p><div><p>Your Signature Is Missing – Act Before It’s Too Late</p><p>Americans who believe in real retirement protection are adding their names to a statement going out to Washing...</p><p><span>American Alternative</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzIzNw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzIzNw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260115160441_pushtrumpnew-5.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260115160441_pushtrumpnew-5.jpg"/></p><div><p>URGENT: Trump Just Triggered AI’s Biggest Disruption Yet</p><p>AI Bombshell: How Wafer-Scale Could Change Data Storage Forever While Wall Street obsesses over public-facing...</p><p><span>Eagle Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzIyOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzIyOQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251013195604_pushtrumpnew-3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251013195604_pushtrumpnew-3.jpg"/></p><div><p>NEW LAW: Congress Approves Setup For Digital Dollar?</p><p>Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0  But according to Rep. Marjorie Taylor ...</p><p><span>Goldco Precious Metals</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzA5Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzA5Ng"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260113092706_pushstock-149421640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260113092706_pushstock-149421640.jpg"/></p><div><p>Buy This Stock at 9:30 AM on MONDAY!</p><p>Recent algorithm alerts have flagged stocks like Nuburu, MSS, and Rebel Holdings ahead of sharp moves — includ...</p><p><span>StocksToTrade</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzE1NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzE1NQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/deductv2.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="797" height="421" original-src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/deductv2.png"/></p><div><p>What Expenses Can Be Deducted From Capital Gains Tax?</p><p>If you’ve built meaningful wealth, capital gains taxes may be quietly taking a larger bite out of your returns...</p><p><span>SmartAsset</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzEyMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzEyMw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260102153335_pushtrumpnew-6.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260102153335_pushtrumpnew-6.jpg"/></p><div><p>Trump just signed it</p><p>A recent policy development is drawing attention from income-focused investors.  According to one analyst, c...</p><p><span>Investors Alley</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzAwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzAwNQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20240930140814_unnamed.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="512" height="338" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20240930140814_unnamed.png"/></p><div><p>BSEM: A $25.50 Price Target, and Nasdaq on the Horizon!</p><p>Bio Stem Technologies Accelerates Into 2026 With Transformative Acquisition, Seven Straight Profitable Quarter...</p><p><span>Huge Alerts</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzM2MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzM2MQ"/></p></div></div></div>                     </div>                 </div></div>

SBIO

<p>Kura Oncology's SVP, Thomas James Doyle, sold 7,142 shares of the company's stock for $60,421.32 at an average price of $8.46 on January 27th. Post-sale, he holds 145,167 shares valued at $1,228,112.82, marking a 4.69% decrease in his ownership. The sale was disclosed to the SEC. Kura's stock opened at $8.47, with a market cap of $737.06 million and a PE ratio of -3.42. Analysts have mixed ratings, with a target price range from $20.00 to $38.00. Hedge funds have also increased their stakes in the company recently.</p>

Market Beat

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Kura Oncology

SPDR S&P Biotech

VG Health

iShares US Pharma

VanEck Biotech ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Kura Oncology (NASDAQ:KURA) SVP Sells $60,421.32 in Stock